These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 37644752)

  • 1. Silencing TRIM29 Sensitizes Non-small Cell Lung Cancer Cells to Anlotinib by Promoting Apoptosis
    Wu M; Jin MM; Cao XH; Zhao L; Li YH
    Curr Cancer Drug Targets; 2024; 24(4):445-454. PubMed ID: 37644752
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RNA editing enzyme adenosine deaminases acting on RNA 1 deficiency increases the sensitivity of non-small cell lung cancer cells to anlotinib by regulating CX3CR1-fractalkine expression.
    Wu M; Jin M; Cao X; Qian K; Zhao L
    Drug Dev Res; 2022 Apr; 83(2):328-338. PubMed ID: 34319598
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NEAT 1 knockdown enhances the sensitivity of human non-small-cell lung cancer cells to anlotinib.
    Gu G; Hu C; Hui K; Chen T; Zhang H; Jiang X
    Aging (Albany NY); 2021 May; 13(10):13941-13953. PubMed ID: 33982669
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transcriptome profiling analysis reveals that CXCL2 is involved in anlotinib resistance in human lung cancer cells.
    Lu J; Xu W; Qian J; Wang S; Zhang B; Zhang L; Qiao R; Hu M; Zhao Y; Zhao X; Han B
    BMC Med Genomics; 2019 Mar; 12(Suppl 2):38. PubMed ID: 30871526
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long non‑coding RNA TP73‑AS1 accelerates the progression and cisplatin resistance of non‑small cell lung cancer by upregulating the expression of TRIM29 via competitively targeting microRNA‑34a‑5p.
    Luo S; Shen M; Chen H; Li W; Chen C
    Mol Med Rep; 2020 Nov; 22(5):3822-3832. PubMed ID: 32901838
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anlotinib can overcome acquired resistance to EGFR-TKIs via FGFR1 signaling in non-small cell lung cancer without harboring EGFR T790M mutation.
    Lian Z; Du W; Zhang Y; Fu Y; Liu T; Wang A; Cai T; Zhu J; Zeng Y; Liu Z; Huang JA
    Thorac Cancer; 2020 Jul; 11(7):1934-1943. PubMed ID: 32433828
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of anlotinib-induced CCL2 decrease in anti-angiogenesis and response prediction for nonsmall cell lung cancer therapy.
    Lu J; Zhong H; Chu T; Zhang X; Li R; Sun J; Zhong R; Yang Y; Alam MS; Lou Y; Xu J; Zhang Y; Wu J; Li X; Zhao X; Li K; Lu L; Han B
    Eur Respir J; 2019 Mar; 53(3):. PubMed ID: 30578392
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Downregulation of MicroRNA-135 Promotes Sensitivity of Non-Small Cell Lung Cancer to Gefitinib by Targeting TRIM16.
    Wang N; Zhang T
    Oncol Res; 2018 Aug; 26(7):1005-1014. PubMed ID: 29295721
    [TBL] [Abstract][Full Text] [Related]  

  • 9. mir-126-5p Promotes Cisplatin Sensitivity of Non-Small-Cell Lung Cancer by Inhibiting ADAM9.
    Liu B; Wang R; Liu H
    Biomed Res Int; 2021; 2021():6622342. PubMed ID: 34055989
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Autophagy inhibition potentiates the anti-angiogenic property of multikinase inhibitor anlotinib through JAK2/STAT3/VEGFA signaling in non-small cell lung cancer cells.
    Liang L; Hui K; Hu C; Wen Y; Yang S; Zhu P; Wang L; Xia Y; Qiao Y; Sun W; Fei J; Chen T; Zhao F; Yang B; Jiang X
    J Exp Clin Cancer Res; 2019 Feb; 38(1):71. PubMed ID: 30755242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. β-Sitosterol attenuates anlotinib resistance in non-small cell lung cancer cells by inhibiting miR-181a-3p/SHQ1 signaling.
    Wang LH; Sun YH; Liu H; Yang X; Wen Z; Tian XF
    Chem Biol Drug Des; 2024 Mar; 103(3):e14493. PubMed ID: 38439529
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Concurrent use of anlotinib overcomes acquired resistance to EGFR-TKI in patients with advanced EGFR-mutant non-small cell lung cancer.
    Zhang C; Cao H; Cui Y; Jin S; Gao W; Huang C; Guo R
    Thorac Cancer; 2021 Oct; 12(19):2574-2584. PubMed ID: 34510760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting Epidermal Growth Factor Receptor by MiRNA-145 Inhibits Cell Growth and Sensitizes NSCLC Cells to Erlotinib.
    Amri J; Molaee N; Baazm M; Karami H
    Asian Pac J Cancer Prev; 2019 Sep; 20(9):2781-2787. PubMed ID: 31554377
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NORAD accelerates chemo-resistance of non-small-cell lung cancer via targeting at miR-129-1-3p/SOX4 axis.
    Huang Q; Xing S; Peng A; Yu Z
    Biosci Rep; 2020 Jan; 40(1):. PubMed ID: 31894841
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exosomal miR-136-5p Derived from Anlotinib-Resistant NSCLC Cells Confers Anlotinib Resistance in Non-Small Cell Lung Cancer Through Targeting PPP2R2A.
    Gu G; Hu C; Hui K; Zhang H; Chen T; Zhang X; Jiang X
    Int J Nanomedicine; 2021; 16():6329-6343. PubMed ID: 34556984
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SNHG7 mediates cisplatin-resistance in non-small cell lung cancer by activating PI3K/AKT pathway.
    Chen K; Abuduwufuer A; Zhang H; Luo L; Suotesiyali M; Zou Y
    Eur Rev Med Pharmacol Sci; 2019 Aug; 23(16):6935-6943. PubMed ID: 31486493
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EHD1 confers resistance to cisplatin in non-small cell lung cancer by regulating intracellular cisplatin concentrations.
    Gao J; Meng Q; Zhao Y; Chen X; Cai L
    BMC Cancer; 2016 Jul; 16():470. PubMed ID: 27411790
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anlotinib Inhibits Cisplatin Resistance in Non-Small-Cell Lung Cancer Cells by Inhibiting MCL-1 Expression via MET/STAT3/Akt Pathway.
    Wang L; Xu L; Han S; Zhu X
    Can Respir J; 2024; 2024():2632014. PubMed ID: 38468814
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Knockdown of TRIM65 inhibits autophagy and cisplatin resistance in A549/DDP cells by regulating miR-138-5p/ATG7.
    Pan X; Chen Y; Shen Y; Tantai J
    Cell Death Dis; 2019 Jun; 10(6):429. PubMed ID: 31160576
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Up-regulation of miR-146a increases the sensitivity of non-small cell lung cancer to DDP by downregulating cyclin J.
    Shi L; Xu Z; Wu G; Chen X; Huang Y; Wang Y; Jiang W; Ke B
    BMC Cancer; 2017 Feb; 17(1):138. PubMed ID: 28202053
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.